IP Library Granted Patent US 11,738,077
Granted Patent B2
US 11,738,077 · App. 17/068,173 · Granted Aug 29, 2023

Immunogenic compositions comprising

Inventors: Jeremy Kroll (Urbandale, IA); Mike Roof (Ames, IA)
A61K39/105A61K39/0241A61K39/0275A61K39/12C12N7/00A61K35/74A61K39/295A61K39/39A61K2039/521A61K2039/522A61K2039/525A61K2039/542A61K2039/55A61K2039/552A61K2039/55566A61K2039/70C12N2750/10034Y02A50/30Y10S424/825
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,738,077
App. No.
17/068,173
Granted
Aug 29, 2023
Kind
B2
Abstract

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Claims (7)

1. A pharmaceutical composition comprising antigens which consist essentially of:

i. killed Lawsonia intracellularis bacterium,

ii. killed Mycoplasma hyopneumoniae.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier is an adjuvant.

4. The pharmaceutical composition of claim 3 , wherein said adjuvant is a water-in-oil emulsion, oil-in-water emulsion or water-in-oil-in-water emulsion.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has between 1×10 2 TCID 50 to 1×10 9 TCID 50 of the killed Lawsonia intracellularis bacterium.

Assignments (2)
MERGER Recorded May 17, 2023
From: BOEHRINGER INGELHEIM VETMEDICA, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 063671/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: KROLL, JEREMY; ROOF, MIKE
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 063672/0824 →
Continuity (6)
Continuation 16226518 · Dec 19, 2018
Continuation 15251308 · Aug 30, 2016
Division 14477694 · Sep 4, 2014
Continuation 11374350 · Mar 13, 2006
Provisional Application 60661352 · Mar 14, 2005
Related Publication 20210030863A1 · Feb 4, 2021